Catalog No.
Product Name
Application
Product Information
Citations
-
Cholinesterase (ChE) Inhibitor
hAChE/Aβ1-42-IN-1 is a potent cholinesterase (ChE) inhibitor that effectively inhibits human acetylcholinesterase (hAChE) and prevents the aggregation of Aβ1-42 peptides. This compound demonstrates favorable relative safety in HepG2 cell lines and exhibits excellent blood-brain barrier (BBB) penetration, exhibiting a wide safety margin. hAChE/Aβ1-42-IN-1 is a valuable tool for research focusing on Alzheimer's disease (AD) and related neurodegenerative conditions. -
Antidepressant Agent
Protriptyline is a potent tricyclic antidepressant (TCA) primarily targeting neurotransmitter reuptake mechanisms. It exhibits significant inhibition of acetylcholinesterase (AChE) activity, with an IC50 value of 0.06 mM, and effectively disrupts Aβ self-assembly. This compound is utilized in research focused on depression and Alzheimer’s disease, providing insights into therapeutic strategies for these conditions. -
Aβ Fragment
Amyloid β-Protein (4-42) is a peptide fragment of the amyloid β-protein that is implicated in the pathogenesis of Alzheimer's disease. This Aβ fragment plays a critical role in the aggregation process that forms amyloid plaques, influencing neurotoxicity and synaptic dysfunction. It is commonly used in research focused on neurodegenerative diseases, enabling studies on amyloid aggregation, cell signaling pathways, and potential therapeutic approaches for Alzheimer's disease. -
BACE1 Inhibitor
AZ3971 is a selective BACE1 inhibitor that effectively penetrates the blood-brain barrier, while leaving γ-secretase activity unaffected. By reducing the production of amyloid-beta (Aβ), AZ3971 serves as a valuable tool in the study of Alzheimer's disease and related neurodegenerative disorders. Its oral bioavailability makes it particularly suitable for in vivo research applications. -
Aβ oligomerization Inhibitor
Aβ aggregation-IN-4 is an Aβ oligomerization inhibitor that targets and mitigates the neurotoxicity associated with amyloid-β protein (Aβ). By significantly reducing the formation of oligomeric complexes of Aβ (Aβ-OCs) without affecting total Aβ levels, it effectively attenuates Aβ oligomerization. This compound provides a valuable tool for researching the pathophysiology of Alzheimer's disease (AD) and exploring potential therapeutic strategies. Additionally, Aβ aggregation-IN-4 protects primary cortical neurons from oligomer-induced cell death, highlighting its relevance in neuroprotective studies. -
Tau/Amyloid-β Aggregation Inhibitor
TRV-1387 is a benzofurazan compound that functions as an inhibitor of tau and amyloid-β aggregation. It demonstrates significant biological activity in preventing the formation of toxic aggregates associated with neurodegenerative diseases, making it a valuable tool for research in Alzheimer's disease and related pathologies. TRV-1387 can be utilized to study the mechanisms of amyloid-related toxicity and to explore potential therapeutic strategies targeting protein aggregation. -
Tau/Aβ Inhibitor
D-687 is a selective inhibitor of Tau and amyloid-beta (Aβ) aggregation. It has demonstrated the ability to reverse Aβ1–42-induced neurotoxicity in SH-SY5Y neuronal cells, highlighting its significant neuroprotective effects. This compound is valuable for research focused on Alzheimer's disease and related neurodegenerative disorders. -
QC Inhibitor
Glutaminyl Cyclase Inhibitor 5 is a potent and selective inhibitor of human glutaminyl cyclase (hQC), exhibiting an IC50 value of 3.2 nM. This compound serves as a valuable tool for investigating the role of hQC in neurodegenerative diseases and related biological processes. It is applicable in various research studies focused on glutamate signaling and its implications in disease mechanisms. -
Amyloid-β Precursor
β-Amyloid Protein Precursor 770 (135-155) is a peptide derived from the amyloid precursor protein isoform APP 770, which plays a crucial role in the generation of amyloid-β peptides Aβ40 and Aβ42. This peptide serves as an important tool for studying the mechanisms of amyloidogenic processing and its implications in neurodegenerative diseases such as Alzheimer’s disease. Researchers can utilize this reagent in assays that investigate protein interactions, amyloid formation, and related signaling pathways. -
Tau/Aβ Inhibitor
D-688 is a potent inhibitor of Tau and amyloid-beta (Aβ), demonstrating significant neuroprotective properties. This compound effectively reverses Aβ1–42-induced toxicity in SH-SY5Y neuronal cells, making it a valuable tool for studying neurodegenerative processes. Additionally, D-688 improves the survival rate of Drosophila melanogaster models expressing the human tau protein isoform (2N4R), underscoring its potential in Alzheimer's disease research and related disorders. -
Amyloid-β
LPYFD-NH2 is a pentapeptide that targets the aggregation of amyloid-β (Aβ(1-42)). It demonstrates inhibitory activity against Aβ aggregation, making it a valuable tool for investigating the pathogenic mechanisms underlying Alzheimer’s disease. This compound is suitable for research applications focused on understanding amyloid-related processes in neurodegeneration. -
Anti-Amyloid-β Antibody
Merinetug is a humanized IgG1κ antibody specifically targeting amyloid beta (Aβ). This antibody plays a crucial role in disrupting the aggregation of Aβ, making it valuable for research into Alzheimer’s disease and related neurodegenerative conditions. Merinetug is utilized in various experimental applications, including therapies aimed at modulating amyloid pathology and understanding the mechanisms underlying amyloid-related neurotoxicity. -
BuChE Inhibitor
BuChE-IN-6 is a potent and selective inhibitor of butyrylcholinesterase (BuChE), exhibiting IC50 values of 0.46 μM and 0.51 μM for equine and human BuChE, respectively. This compound also demonstrates the ability to inhibit self-aggregation of amyloid-beta 42 (Aβ42), making it a valuable tool for research related to neurodegenerative diseases. Its unique properties support investigations into cholinergic dysfunction and the pathogenesis of Alzheimer's disease. -
Lipid Droplet Formation Inhibitor
Beauveriolide III is a specific inhibitor of lipid droplet formation, effectively reducing lipid accumulation in mouse macrophages. This compound plays a significant role in studies focused on lipid metabolism and its implications in metabolic disorders. Its utility in research can aid in understanding the biological pathways regulating lipid storage and inflammation in macrophage-associated pathologies. -
Amyloid β-Protein (1-40) Fluorescence
5-TAMRA-Amyloid β-Protein (1-40) is a fluorescently labeled peptide targeting the Amyloid β-Protein (1-40) with an excitation/emission wavelength of 544/572 nm. This reagent is designed for the study of amyloid aggregation, facilitating the investigation of Alzheimer's disease pathology. Its fluorescence properties make it suitable for applications in live-cell imaging and fluorescence microscopy, enabling researchers to track amyloid formation and accumulation in various biological contexts. -
AD Molecular Probe
Aftobetin is a non-invasive molecular probe targeting aggregated β-amyloid peptides (Aβ) for the early diagnosis of Alzheimer's disease (AD). This reagent can specifically bind to Aβ aggregates present in the lens of the eye, facilitating rapid and painless detection of AD in patients. Aftobetin serves as a valuable tool in both clinical diagnostics and research applications focused on neurodegenerative disease mechanisms. -
Amyloid-β
SCH 900229 is a selective γ-secretase inhibitor targeting presenilin 1 (PS1) with an Aβ40 IC50 value of 1.3 nM, demonstrating strong efficacy in reducing amyloid-β levels. This compound exhibits significant Aβ-lowering effects following oral administration in preclinical animal models. It has progressed to human clinical trials as a potential therapeutic agent for Alzheimer's disease, highlighting its relevance in neurodegenerative research. -
hAChE/hBACE Inhibitor
hAChE/hBACE-1-IN-4 is a quinazoline derivative that functions as a dual inhibitor of human acetylcholinesterase (hAChE) and human β-site amyloid precursor protein cleaving enzyme 1 (hBACE-1). It exhibits potent inhibitory activity with IC50 values of 0.283 μM for hAChE and 0.231 μM for hBACE-1. This compound demonstrates the ability to inhibit amyloid-beta (Aβ) aggregation and shows favorable properties such as non-neurotoxicity, blood-brain barrier permeability, and oral bioavailability. hAChE/hBACE-1-IN-4 is suitable for research applications related to Alzheimer's disease. -
RAGE/SERT Inhibitor
RAGE/SERT-IN-1 is a potent inhibitor of receptor for advanced glycation end products (RAGE) and serotonin transporter (SERT), demonstrating IC50 values of 8.26 μM and 31.09 nM, respectively. This compound exhibits significant neuroprotective properties against Aβ25-35-induced neuronal damage and has been shown to alleviate depressive behaviors in murine models. RAGE/SERT-IN-1 is a valuable tool for studying the interplay between Alzheimer's disease and depression comorbidity. -
Aβ Aggregation Inhibitor
SEN 304 is an Aβ aggregation inhibitor that directly binds to Aβ(1-42), effectively delaying β-sheet formation while promoting the aggregation of toxic oligomers into a nontoxic form. This compound is primarily utilized in research focused on Alzheimer’s disease, providing insights into the mechanisms of neurodegeneration and potential therapeutic strategies. The ability of SEN 304 to modulate Aβ aggregation makes it a valuable tool for studying amyloid pathology. -
AChE Inhibitor
AChE-IN-19 is a potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 0.56 μM. This compound also demonstrates the ability to inhibit amyloid beta (Aβ) aggregation, contributing to its neuroprotective properties. AChE-IN-19 has been shown to exert minimal toxicity on SH-SY5Y neuronal cells, making it a valuable tool for research applications related to Alzheimer's disease. -
Anti-aggregation Compound
2,3-Dehydrosilybin A is an anti-aggregation compound that targets protein misfolding. This compound exhibits significant potential in preventing amyloid formation and related neurodegenerative disorders. Research applications include studying its impact on cellular longevity and its role in mitigating protein aggregation, making it valuable for exploring therapeutic approaches for age-related diseases. -
Amyloid-β Inhibitor
Aβ Fibrillization Modulator 1 targets amyloid-β (Aβ) by stabilizing Aβ monomers, thus inhibiting the formation of toxic fibrils associated with neurodegenerative diseases. This compound demonstrates potential in research applications focused on Alzheimer's disease and other amyloid-related disorders. By modulating fibrillization, it provides a valuable tool for investigating the mechanisms of amyloid aggregation and the development of therapeutic strategies. -
Amyloid-β Inhibitor
AChE/Aβ-IN-5 is a bifunctional inhibitor that targets acetylcholinesterase (AChE) and reduces the auto-induced aggregation of amyloid-β (Aβ) peptides. This compound has demonstrated the ability to significantly ameliorate cognitive deficits induced by scopolamine and Aβ in murine models. It serves as a valuable tool for research into neurodegenerative diseases, particularly Alzheimer's disease, by providing insights into the mechanisms underlying cognitive impairment. -
Aβ42 Inhibitor
2002-G12 is an Aβ42 inhibitor that effectively reduces Aβ42 toxicity by 76%. Its mechanism of action makes it a valuable tool for investigating Alzheimer's disease and studying the role of Aβ42 in neurodegenerative processes. Researchers can utilize 2002-G12 to explore potential therapeutic strategies targeting amyloid-beta aggregation and toxicity. -
Amyloid-β Inhibitor
KMS88009 is a potent amyloid-β oligomer inhibitor that directly disrupts the formation of these aggregates. This compound demonstrates significant potential in preserving cognitive function when administered preventively and reversing cognitive decline therapeutically. In studies using the APP/PS1 double transgenic mouse model, KMS88009 effectively reduced amyloid-β oligomer assembly and improved cognitive performance. Comprehensive evaluations of its physicochemical properties, pharmacokinetics, and toxicity further underscore KMS88009's promise as a therapeutic candidate for Alzheimer's disease. -
Amyloid-β
β-Amyloid (33-40) is a peptide derived from the beta-amyloid protein, encompassing amino acids 33 to 40. This peptide serves as a key target for studies investigating the aggregation processes related to neurodegenerative diseases, particularly Alzheimer’s disease. Its biological activity is critical for understanding amyloid pathology and exploring potential therapeutic strategies in Alzheimer’s research. -
Aβ Fragment
β Amyloid (3-40) is a fragment of amyloid-beta (Aβ) that plays a critical role in Alzheimer's disease pathology. This peptide is involved in the aggregation processes that lead to the formation of amyloid plaques in the brain. Research applications include studies of neurodegeneration, cellular toxicity, and the molecular mechanisms underlying Alzheimer's disease. Its use provides insights into potential therapeutic targets and pathways for intervention in age-related cognitive decline. -
AChE Inhibitor
Memoquin is an AChE inhibitor with significant anti-amyloid and antioxidant properties. It exhibits oral bioavailability and selectively inhibits BACE-1 and AChE, with IC50 values of 108 nM and 1.55 nM, respectively. Memoquin is noted for its ability to enhance cognitive function while preventing Aβ-induced neurotoxicity associated with oxidative stress. This compound is valuable for research into Alzheimer's disease and related neurodegenerative disorders. -
Beta-secretase inhibitor
β-Secretase-IN-5 is a potent inhibitor of beta-secretase, a key enzyme involved in the cleavage of amyloid precursor protein (APP). By selectively reducing the production of amyloid-beta peptides Aβ1-40 and Aβ1-42, this compound is essential for research into Alzheimer's disease mechanisms and therapeutic strategies. Its application in neurodegenerative studies provides valuable insights into potential treatments for Alzheimer's. -
AChE Inhibitor
Phenserine tartrate is a selective, noncompetitive inhibitor of acetylcholinesterase (AChE) derived from Physostigmine. This compound has been shown to reduce the formation of β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ), key factors involved in Alzheimer's disease pathology. Phenserine tartrate has demonstrated potential in improving cognitive performance and may help slow the progression of Alzheimer's disease, making it a valuable tool for research in neurodegenerative disorders. -
FAM-labeled β-Amyloid (1-40)
β-Amyloid (1-40), FAM-labeled is a fluorescently labeled peptide that targets amyloid plaques associated with Alzheimer's disease. With an excitation wavelength of 492 nm and an emission wavelength of 518 nm, this FAM-tagged β-Amyloid (1-40) enables sensitive detection and visualization of amyloid aggregates in various biological samples. It can be utilized in research applications focused on neurodegenerative disorders, helping to elucidate the pathophysiological role of β-amyloid peptides in Alzheimer's disease progression. -
ChE/Aβ1-42 Aggregation Inhibitor
ChE/Aβ1-42-IN-1 is a potent inhibitor of acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and amyloid-beta peptide (Aβ1-42) aggregation, exhibiting IC50 values of 0.062 µM, 0.767 µM, and 1.227 µM, respectively. This compound demonstrates significant blood-brain barrier (BBB) penetration, making it a promising candidate for research into Alzheimer's disease. ChE/Aβ1-42-IN-1's multi-targeted mechanism positions it as a valuable tool for studying therapeutic strategies in neurodegenerative disorders. -
Aβ Fragment
Amyloid β-Protein (16-22) is a fragment of the amyloid precursor protein, specifically targeting the aggregation processes associated with Alzheimer's disease. This peptide plays a crucial role in the study of amyloid plaque formation and neurotoxicity. Its biological activity is essential for researchers investigating the pathophysiology of Alzheimer's and for developing potential therapeutic strategies to combat amyloid-related disorders. -
Aβ Fragment
β Amyloid (11-42) is a fragment of the amyloid precursor protein, primarily targeting the formation of amyloid plaques in the brain. This peptide plays a crucial role in Alzheimer’s disease research, serving as a key biomarker for studying neurodegeneration and associated pathology. It is widely used in assays to investigate amyloid aggregation and its impact on neuronal function, making it an essential reagent for exploring therapeutic strategies against Alzheimer's disease. -
Aβ Aggregation Inhibitor
SEN-1269 is a potent inhibitor of Aβ aggregation, specifically targeting Aβ(1-42) oligomers. This compound protects neuronal cell lines from the detrimental effects of Aβ(1-42) exposure and mitigates deficits in long-term potentiation (LTP) and memory associated with Aβ oligomer toxicity. SEN-1269 serves as a valuable tool for research investigating the pathophysiology of Alzheimer's disease. -
Tau Imaging Ligand
THK-523 is a selective tau imaging ligand that targets tau pathology associated with neurodegenerative disorders, particularly Alzheimer's disease. Demonstrating high affinity and specificity, THK-523 is effective as an in vivo radiotracer, facilitating the imaging of tau aggregates. Its applications extend to research in tau-related pathologies, aiding in the understanding of tau's role in neurodegeneration and the development of potential therapeutic strategies. -
Amyloid Probe
Chrysamine G is a carboxylic acid analogue of Congo Red, primarily utilized as a probe for detecting amyloid deposition associated with Alzheimer's disease. This compound exhibits significant biological activity by inhibiting Aβ-induced cytotoxicity in PC12 cells, making it a valuable tool in Alzheimer's research and studies focused on amyloid pathology. -
AChE Inhibitor
hAChE-IN-10 is a potent inhibitor of human acetylcholinesterase (AChE), demonstrating an IC50 of 6.34 nM. This compound exhibits significant antioxidant properties and effectively scavenges free radicals. Additionally, hAChE-IN-10 has been shown to inhibit Cu2+-induced aggregation of Aβ1-42, reduce amyloid plaque formation, and provide neuroprotective effects. It has also been linked to the improvement of cognitive deficits in mouse models induced by scopolamine, making it a valuable tool for studying neurodegenerative diseases and cognitive impairment. -
Aβ42 Inhibitor
GL-522, a 4-sulfocalix[8]arene derivative, functions as an Aβ42 inhibitor by engaging in nonspecific and multipoint hydrophobic interactions, exhibiting a Kd of 276 μM. This compound effectively inhibits the fibrillation of Aβ42 and mitigates its cytotoxic effects, making it a valuable tool for research in Alzheimer's disease. Its ability to modulate amyloid aggregation and toxicity positions GL-522 as a significant reagent in neurodegenerative disease studies. -
Aβ Fragment
Amyloid β-Protein (1-46) is a fragment of the amyloid precursor protein that primarily targets amyloid aggregation processes. This peptide is crucial for studying the formation and deposition of amyloid plaques, which are characteristic of Alzheimer's disease pathology. It serves as an important tool for research applications aimed at understanding neurodegenerative mechanisms and testing potential therapeutic agents. -
Mucofluidifying Agent
trans-Sobrerol is a potent mucofluidifying agent that acts primarily to enhance hippocampal cholinergic signaling. It exhibits significant anti-amnesic effects, demonstrating properties that counteract tau hyperphosphorylation and Aβ synthesis. Furthermore, trans-Sobrerol effectively alleviates memory impairment induced by scopolamine, making it a valuable tool for investigating mechanisms underlying Alzheimer's disease. -
Aβ Aggregation Inhibitor
AY1511 is an amyloid β (Aβ) aggregation inhibitor that demonstrates low cytotoxicity. This compound is utilized in research focusing on neurodegenerative diseases, particularly Alzheimer's disease, by inhibiting the aggregation of Aβ peptides. AY1511 serves as a valuable tool for studying the mechanisms of amyloid pathology and the development of potential therapeutic strategies. -
Aβ40/tau Aggregation Inhibitor
Tau/Aβ40 aggregation-IN-1 is a potent inhibitor of tau and Aβ40 aggregation, exhibiting IC50 values of 1.8 μM and 1.3 μM, respectively. This compound is of significant interest in Alzheimer's disease research, as it targets the pathological aggregation of tau protein and amyloid-beta peptides. Its effectiveness in modulating these protein interactions makes it a valuable tool for studying neurodegenerative mechanisms and potential therapeutic interventions. -
paeonol derivative
6′-Methyl paeonol is a derivative of paeonol that primarily targets neuronal pathways. It demonstrates inhibitory effects on abnormal depolarizations and reduces Amyloid β-induced ERK phosphorylation. This compound shows promise for alleviating symptoms associated with Alzheimer's Disease, making it a valuable tool for research in neurodegenerative disorders. -
Amyloid-β
β-Amyloid (22-40) is a peptide fragment derived from the amyloid precursor protein, primarily targeting amyloid-β. This fragment is pivotal in the study of amyloid aggregation and plaque formation associated with Alzheimer's disease. Its application in research includes elucidating amyloid pathophysiology and screening potential therapeutic compounds for neurodegenerative disorders. -
MAO-B Inhibitor
MAO-B-IN-50 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 value of 0.06 μM. This compound is effective in inhibiting the aggregation of amyloid-beta (Aβ40/42) and Tau proteins, with overall IC50 values near 1 μM. Additionally, MAO-B-IN-50 shows potent selective inhibition of acetylcholinesterase (AChE) with an IC50 of 1.78 μM. It is suitable for use in research related to Alzheimer's disease. -
Amyloid β Inhibitor
Aβ-IN-4 is a potent inhibitor of amyloid β (Aβ) aggregation, specifically targeting Aβ42. It effectively halts the aggregation process of Aβ42, which is central to the pathogenesis of Alzheimer’s disease. However, Aβ-IN-4 does not mitigate the neurotoxicity associated with Aβ42 in SH-SY5Y cells, nor does it modify the aggregation state of Aβ42 into a non-toxic form. This compound is valuable for research investigating Aβ-related mechanisms and the development of Alzheimer’s therapeutics. -
AChE Inhibitor
AChE-IN-12 is a selective acetylcholinesterase (AChE) inhibitor that effectively penetrates the blood-brain barrier, exhibiting IC50 values of 0.41 μM for rat AChE and 1.88 μM for electric eel AChE. This compound also demonstrates antioxidant properties (ORAC = 3.3 eq), selectively chelates metals, and inhibits human monoamine oxidase B (MAO-B) with an IC50 of 8.8 μM. AChE-IN-12 significantly inhibits both self- and Cu2+-induced aggregation of Aβ1-42 and displays neuroprotective effects, making it a valuable tool for research related to Alzheimer’s disease. -
AChE/BuChE Inhibitor
AChE/BuChE-IN-3 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), exhibiting IC50 values of 0.65 μM and 5.77 μM, respectively. This compound effectively inhibits the aggregation of amyloid beta peptide Aβ1-42 and demonstrates neuroprotective properties with minimal toxicity in SH-SY5Y cells. AChE/BuChE-IN-3 is suitable for research applications related to Alzheimer's disease, providing insight into cholinergic system modulation and potential therapeutic strategies.
